Frontiers in the surgical treatment of Parkinson’s disease

References

• Limousin P, Krack P, Pollak P et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N. Engl. J. Med.339(16), 1105–1111 (1998).
   PubMed Web of Science ®Google Scholar
• Krack P, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N. Engl. J. Med.349(20), 1925–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N. Engl. J. Med.355(9), 896–908 (2006).
   PubMed Web of Science ®Google Scholar
• Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl. Neurophysiol.50(1–6), 344–346 (1987).
   PubMedGoogle Scholar
• Siegfried J. [Effect of stimulation of the sensory nucleus of the thalamus on dyskinesia and spasticity]. Rev. Neurol. (Paris)142(4), 380–383 (1986).
   PubMed Web of Science ®Google Scholar
• Siegfried J, Lippitz B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all Parkinsonian symptoms. Neurosurgery35(6), 1126–1129; discussion 1129–1130 (1994).
   PubMed Web of Science ®Google Scholar
• Burchiel KJ, Anderson VC, Favre J, Hammerstad JP. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson’s disease: results of a randomized, blinded pilot study. Neurosurgery45(6), 1375–1382; discussion 1382–1384 (1999).
   PubMed Web of Science ®Google Scholar
• Limousin P, Pollak P, Benazzouz A et al. Effect of Parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet345(8942), 91–95 (1995).
   PubMed Web of Science ®Google Scholar
• Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat. Disord.12(5), 265–272 (2006).
   PubMed Web of Science ®Google Scholar
• Peppe A, Pierantozzi M, Bassi A et al. Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease. J. Neurosurg.101(2), 195–200 (2004).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Oroz MC, Obeso JA, Lang AE et al. Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain128(Pt 10), 2240–2249 (2005).
   PubMed Web of Science ®Google Scholar
• Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain123(Pt 9), 1767–1783 (2000).
   PubMed Web of Science ®Google Scholar
• Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson’s disease. Ann. Neurol.26(1), 41–46 (1989).
   PubMed Web of Science ®Google Scholar
• Nandi D, Liu X, Winter JL, Aziz TZ, Stein JF. Deep brain stimulation of the pedunculopontine region in the normal non-human primate. J. Clin. Neurosci.9(2), 170–174 (2002).
   PubMed Web of Science ®Google Scholar
• Nandi D, Aziz TZ, Giladi N, Winter J, Stein JF. Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. Brain125(Pt 11), 2418–2430 (2002).
   PubMed Web of Science ®Google Scholar
• Jenkinson N, Nandi D, Miall RC, Stein JF, Aziz TZ. Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. Neuroreport15(17), 2621–2624 (2004).
   PubMed Web of Science ®Google Scholar
• Mazzone P, Lozano A, Stanzione P et al. Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson’s disease. Neuroreport16(17), 1877–1881 (2005).
   PubMed Web of Science ®Google Scholar
• Stefani A, Lozano AM, Peppe A et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain130(Pt 6), 1596–1607 (2007).
   PubMed Web of Science ®Google Scholar
• Plaha P, Gill SS. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s disease. Neuroreport16(17), 1883–1887 (2005).
   PubMed Web of Science ®Google Scholar
• Plaha P, Ben-Shlomo Y, Patel NK, Gill SS. Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Brain129(Pt 7), 1732–1747 (2006).
   PubMed Web of Science ®Google Scholar
• Jiménez F, Velasco F, Velasco M et al. Subthalamic prelemniscal radiation stimulation for the treatment of Parkinson’s disease: electrophysiological characterization of the area. Arch. Med. Res.31(3), 270–281 (2000).
   PubMedGoogle Scholar
• Kitagawa M, Murata J, Uesugi H et al. Two-year follow-up of chronic stimulation of the posterior subthalamic white matter for tremor-dominant Parkinson’s disease. Neurosurgery56(2), 281–289 (2005).
   PubMed Web of Science ®Google Scholar
• Katayama Y, Fukaya C, Yamamoto T. Control of poststroke involuntary and voluntary movement disorders with deep brain or epidural cortical stimulation. Stereotact. Funct. Neurosurg.69(1–4 Pt 2), 73–79 (1997).
   PubMed Web of Science ®Google Scholar
• García-Larrea L, Peyron R, Mertens P et al. Electrical stimulation of motor cortex for pain control: a combined PET-scan and electrophysiological study. Pain83(2), 259–273 (1999).
   PubMed Web of Science ®Google Scholar
• Canavero S, Paolotti R, Bonicalzi V et al. Extradural motor cortex stimulation for advanced Parkinson disease. Report of two cases. J. Neurosurg.97(5), 1208–1211 (2002).
   PubMed Web of Science ®Google Scholar
• Cioni B. Motor cortex stimulation for Parkinson’s disease. Acta Neurochir. Suppl.97(Pt 2), 233–238 (2007).
   PubMedGoogle Scholar
• Pagni CA, Altibrandi MG, Bentivoglio A et al. Extradural motor cortex stimulation (EMCS) for Parkinson’s disease. History and first results by the study group of the Italian neurosurgical society. Acta Neurochir. Suppl.93, 113–119 (2005).
   PubMedGoogle Scholar
• Temel Y, Visser-Vandewalle V. Targets for deep brain stimulation in Parkinson’s disease. Expert Opin. Ther. Targets10(3), 355–362 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for neuroprotection. Ann. Neurol.44(3 Suppl. 1), S175–S188 (1998).
   PubMed Web of Science ®Google Scholar
• Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur. J. Neurosci.8(7), 1408–1414 (1996).
   PubMed Web of Science ®Google Scholar
• Chen L, Liu Z, Tian Z, Wang Y, Li S. Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions. Stereotact. Funct. Neurosurg.75(2–3), 66–75 (2000).
   PubMedGoogle Scholar
• Carvalho GA, Nikkhah G. Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp. Neurol.171(2), 405–417 (2001).
   PubMedGoogle Scholar
• Paul G, Meissner W, Rein S et al. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson’s disease. Exp. Neurol.185(2), 272–280 (2004).
   PubMed Web of Science ®Google Scholar
• Nakao N, Nakai E, Nakai K, Itakura T. Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann. Neurol.45(5), 640–651 (1999).
   PubMedGoogle Scholar
• Maesawa S, Kaneoke Y, Kajita Y et al. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. J. Neurosurg.100(4), 679–687 (2004).
   PubMed Web of Science ®Google Scholar
• Temel Y, Visser-Vandewalle V, Kaplan S et al. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res.1120(1), 100–105 (2006).
   PubMed Web of Science ®Google Scholar
• Wallace BA, Ashkan K, Heise CE et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain130(Pt 8), 2129–2145 (2007).
   PubMed Web of Science ®Google Scholar
• Luquin MR, Saldise L, Guillén J et al. Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson’s disease? Exp. Neurol.201(2), 407–415 (2006).
   PubMedGoogle Scholar
• Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano AM, Lang AE. Longjterm follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J. Neurosurg.99(3), 489–495 (2003).
   PubMed Web of Science ®Google Scholar
• Hilker R, Portman AT, Voges J et al. Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation. J. Neurol. Neurosurg. Psychiatry76(9), 1217–1221 (2005).
   PubMed Web of Science ®Google Scholar
• Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science260(5111), 1130–1132 (1993).
   PubMed Web of Science ®Google Scholar
• Schaar DG, Sieber BA, Dreyfus CF, Black IB. Regional and cell-specific expression of GDNF in rat brain. Exp. Neurol.124(2), 368–371 (1993).
   PubMed Web of Science ®Google Scholar
• Beck KD, Valverde J, Alexi T et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature373(6512), 339–341 (1995).
   PubMed Web of Science ®Google Scholar
• Tomac A, Lindqvist E, Lin LF et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo.. Nature373(6512), 335–339 (1995).
   PubMed Web of Science ®Google Scholar
• Gash DM, Zhang Z, Ovadia A et al. Functional recovery in Parkinsonian monkeys treated with GDNF. Nature380(6571), 252–255 (1996).
   PubMed Web of Science ®Google Scholar
• Olson L. Toward trophic treatment in parkinsonism: a primate step. Nat. Med.2(4), 400–401 (1996).
   PubMedGoogle Scholar
• Lapchak PA, Gash DM, Collins F, Hilt D, Miller PJ, Araujo DM. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson’s disease. Exp. Neurol.145(2 Pt 1), 309–321 (1997).
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Gash DM, Jiao S, Miller PJ, Hilt D. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson’s disease. Exp. Neurol.144(1), 29–34 (1997).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Burchiel KJ, Comella CL et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology60(1), 69–73 (2003).
   PubMed Web of Science ®Google Scholar
• Gill SS, Patel NK, Hotton GR et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med.9(5), 589–595 (2003).
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol.59(3), 459–466 (2006).
   PubMed Web of Science ®Google Scholar
• Patel NK, Gill SS. GDNF delivery for Parkinson’s disease. Acta Neurochir. Suppl.97(Pt 2), 135–154 (2007).
   PubMedGoogle Scholar
• Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med.11(7), 703–704 (2005).
   PubMed Web of Science ®Google Scholar
• Kotzbauer PT, Lampe PA, Heuckeroth RO et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature384(6608), 467–470 (1996).
   PubMed Web of Science ®Google Scholar
• Horger BA, Nishimura MC, Armanini MP et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci.18(13), 4929–4937 (1998).
   PubMed Web of Science ®Google Scholar
• Oiwa Y, Yoshimura R, Nakai K, Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson’s disease. Brain Res.947(2), 271–283 (2002).
   PubMedGoogle Scholar
• Quartu M, Serra MP, Manca A, Mascia F, Follesa P, Del Fiacco M. Neurturin, persephin, and artemin in the human pre- and full-term newborn and adult hippocampus and fascia dentata. Brain Res.1041(2), 157–166 (2005).
   PubMedGoogle Scholar
• Masure S, Geerts H, Cik M et al. Enovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells. Existence and tissue-specific expression of different splice variants. Eur. J. Biochem.266(3), 892–902 (1999).
   PubMedGoogle Scholar
• Baloh RH, Tansey MG, Lampe PA et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex. Neuron21(6), 1291–1302 (1998).
   PubMed Web of Science ®Google Scholar
• Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science204(4393), 643–647 (1979).
   PubMed Web of Science ®Google Scholar
• Brundin P, Nilsson OG, Strecker RE, Lindvall O, Astedt B, Björklund A. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson’s disease. Exp. Brain Res.65(1), 235–240 (1986).
   PubMed Web of Science ®Google Scholar
• Bankiewicz KS, Plunkett RJ, Mefford I, Kopin IJ, Oldfield EH. Behavioral recovery from MPTP-induced parkinsonism in monkeys after intracerebral tissue implants is not related to CSF concentrations of dopamine metabolites. Prog. Brain Res.82, 561–571 (1990).
   PubMedGoogle Scholar
• Freed CR, Breeze RE, Rosenberg NL et al. Transplantation of human fetal dopamine cells for Parkinson’s disease. Results at 1 year. Arch. Neurol.47(5), 505–512 (1990).
   PubMedGoogle Scholar
• Lindvall O, Brundin P, Widner H et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science247(4942), 574–577 (1990).
   PubMed Web of Science ®Google Scholar
• Freed CR, Breeze RE, Rosenberg NL et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N. Engl. J. Med.327(22), 1549–1555 (1992).
   PubMed Web of Science ®Google Scholar
• Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N. Engl. J. Med.344(10), 710–719 (2001).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann. Neurol.54(3), 403–414 (2003).
   PubMed Web of Science ®Google Scholar
• Piccini P, Pavese N, Hagell P et al. Factors affecting the clinical outcome after neural transplantation in Parkinson’s disease. Brain128(Pt 12), 2977–2986 (2005).
   PubMed Web of Science ®Google Scholar
• Perrier AL, Tabar V, Barberi T et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl Acad. Sci. USA101(34), 12543–12548 (2004).
   PubMed Web of Science ®Google Scholar
• Bjorklund LM, Sánchez-Pernaute R, Chung S et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl Acad. Sci. USA99(4), 2344–2349 (2002).
   PubMed Web of Science ®Google Scholar
• Takagi Y, Takahashi J, Saiki H et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J. Clin. Invest.115(1), 102–109 (2005).
   PubMed Web of Science ®Google Scholar
• Brederlau A, Correia AS, Anisimov SV et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells24(6), 1433–1440 (2006).
   PubMed Web of Science ®Google Scholar
• Ben-Hur T, Idelson M, Khaner H et al. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells22(7), 1246–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Torres EM, Monville C, Lowenstein PR, Castro MG, Dunnett SB. Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson’s disease using adenoviral vectors increased yield of dopamine cells is dependent on embryonic donor age. Brain Res. Bull.68(1–2), 31–41 (2005).
   PubMed Web of Science ®Google Scholar
• Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in Parkinsonian rats. Nat. Neurosci.1(4), 290–295 (1998).
   PubMed Web of Science ®Google Scholar
• Wang X, Lu Y, Zhang H et al. Distinct efficacy of pre-differentiated versus intact fetal mesencephalon-derived human neural progenitor cells in alleviating rat model of Parkinson’s disease. Int. J. Dev. Neurosci.22(4), 175–183 (2004).
   PubMedGoogle Scholar
• Parati EA, Bez A, Ponti D, Sala S, Pozzi S, Pagano SF. Neural stem cells. Biological features and therapeutic potential in Parkinson’s disease. J. Neurosurg. Sci.47(1), 8–17 (2003).
   PubMedGoogle Scholar
• Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: cells bearing neuronal antigens generated in vivo. from bone marrow. Science290(5497), 1779–1782 (2000).
   PubMed Web of Science ®Google Scholar
• Toma JG, Akhavan M, Fernandes KJ et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat. Cell Biol.3(9), 778–784 (2001).
   PubMed Web of Science ®Google Scholar
• Fu YS, Cheng YC, Lin MY et al. Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. Stem Cells24(1), 115–124 (2006).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Gómez JA, Lu JQ, Velasco I et al. Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells25(4), 918–928 (2007).
   PubMedGoogle Scholar
• Li XK, Guo AC, Zuo PP. Survival and differentiation of transplanted neural stem cells in mice brain with MPTP-induced Parkinson disease. Acta Pharmacol. Sin.24(12), 1192–1198 (2003).
   PubMed Web of Science ®Google Scholar
• Hovakimyan M, Haas SJ, Schmitt O, Gerber B, Wree A, Andressen C. Mesencephalic human neural progenitor cells transplanted into the neonatal hemiparkinsonian rat striatum differentiate into neurons and improve motor behaviour. J. Anat.209(6), 721–732 (2006).
   PubMedGoogle Scholar
• Redmond DE, Bjugstad KB, Teng YD et al. Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells. Proc. Natl Acad. Sci. USA104(29), 12175–12180 (2007).
   PubMed Web of Science ®Google Scholar
• Richardson RM, Broaddus WC, Holloway KL, Fillmore HL. Grafts of adult subependymal zone neuronal progenitor cells rescue hemiparkinsonian behavioral decline. Brain Res.1032(1–2), 11–22 (2005).
   PubMedGoogle Scholar
• Yasuhara T, Matsukawa N, Hara K et al. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson’s disease. J. Neurosci.26(48), 12497–12511 (2006).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131(5), 861–872 (2007).
   PubMed Web of Science ®Google Scholar
• Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science318(5858), 1917–1920 (2007).
   PubMed Web of Science ®Google Scholar
• Subramanian T, Marchionini D, Potter EM, Cornfeldt ML. Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant.11(3), 207–214 (2002).
   PubMed Web of Science ®Google Scholar
• Subramanian T, Bakay RAE, Cornfeldt ME, Watts RL. Blinded placebo-controlled trial to assess the effects of striatal transplantation of human retinal pigmented epithelial cells attached to microcarriers (hRPE-M) in Parkinsonian monkeys. Parkinsonism Relat. Disord.5, S111 (1999).
   PubMedGoogle Scholar
• Stover NP, Bakay RA, Subramanian T et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch. Neurol.62(12), 1833–1837 (2005).
   PubMed Web of Science ®Google Scholar
• Betchen SA, Kaplitt M. Future and current surgical therapies in Parkinson’s disease. Curr. Opin. Neurol.16(4), 487–493 (2003).
   PubMedGoogle Scholar
• Bensadoun JC, Déglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson’s disease using GDNF. Exp. Neurol.164(1), 15–24 (2000).
   PubMed Web of Science ®Google Scholar
• Brizard M, Carcenac C, Bemelmans AP, Feuerstein C, Mallet J, Savasta M. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson’s disease. Neurobiol. Dis.21(1), 90–101 (2006).
   PubMed Web of Science ®Google Scholar
• Fjord-Larsen L, Johansen JL, Kusk P et al. Efficient in vivo. protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp. Neurol.195(1), 49–60 (2005).
   PubMed Web of Science ®Google Scholar
• Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease. Brain Res.1052(2), 119–129 (2005).
   PubMed Web of Science ®Google Scholar
• Gasmi M, Brandon EP, Herzog CD et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson’s disease. Neurobiol. Dis.27(1), 67–76 (2007).
   PubMed Web of Science ®Google Scholar
• Kordower JH, Emborg ME, Bloch J et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science290(5492), 767–773 (2000).
   PubMed Web of Science ®Google Scholar
• Palfi S, Leventhal L, Chu Y et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci.22(12), 4942–4954 (2002).
   PubMed Web of Science ®Google Scholar
• Sánchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz KS. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol. Ther.4(4), 324–330 (2001).
   PubMed Web of Science ®Google Scholar
• Bencsics C, Wachtel SR, Milstien S, Hatakeyama K, Becker JB, Kang UJ. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. J. Neurosci.16(14), 4449–4456 (1996).
   PubMed Web of Science ®Google Scholar
• Kang UJ, Nakamura K. Potential of gene therapy for pediatric neurotransmitter diseases: lessons from Parkinson’s disease. Ann. Neurol.54(Suppl. 6), S103–S109 (2003).
   Google Scholar
• During MJ, Samulski RJ, Elsworth JD et al.In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther.5(6), 820–827 (1998).
   PubMed Web of Science ®Google Scholar
• Muramatsu S, Fujimoto K, Ikeguchi K et al. Behavioral recovery in a primate model of Parkinson’s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther.13(3), 345–354 (2002).
   PubMed Web of Science ®Google Scholar
• During MJ, Kaplitt MG, Stern MB, Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther.12(12), 1589–1591 (2001).
   PubMedGoogle Scholar
• Lo Bianco C, Schneider BL, Bauer M et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson’s disease. Proc. Natl Acad. Sci. USA101(50), 17510–17515 (2004).
   PubMed Web of Science ®Google Scholar
• Luo J, Kaplitt MG, Fitzsimons HL et al. Subthalamic GAD gene therapy in a Parkinson’s disease rat model. Science298(5592), 425–429 (2002).
   PubMed Web of Science ®Google Scholar
• Kaplitt MG, Feigin A, Tang C et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, Phase I trial. Lancet369(9579), 2097–2105 (2007).
   PubMed Web of Science ®Google Scholar